Company Overview of Envisia Therapeutics Inc.
Envisia Therapeutics Inc. is engaged in the discovery and development of ocular therapeutics for the critical needs in ophthalmology. The company offers ENV515, a prostaglandin analogue that uses a biodegradable PRINT particle formulation to provide sustained intraocular pressure reduction over months. It also provides glaucoma drug therapies that include PRINT particle therapeutics to overcome biologic, chemical, or other barriers that limit existing ocular therapies; therapeutics based on biocompatible polymers for the delivery of medicines with extended-release kinetics; and topical therapies for treating ocular diseases. The company was founded in 2013 and is based in Morrisville, North ...
419 Davis Drive
Morrisville, NC 27560
Founded in 2013
Key Executives for Envisia Therapeutics Inc.
Chief Executive Officer and Director
Co-Founder, President and Chief Scientific Officer
Compensation as of Fiscal Year 2014.
Envisia Therapeutics Inc. Key Developments
Envisia Therapeutics Appoints Rhett M. Schiffman as Chief Medical Officer and Senior Vice President of Development
Apr 14 15
Envisia Therapeutics announced that it has named Rhett M. Schiffman M.D., M.S., M.H.S. A as Chief Medical Officer and Senior Vice President of Development. Prior to Envisia, Dr. Schiffman was the Chief Medical Officer at Neurotech Pharmaceuticals where he led the company’s NT-503 program. He brings with him more than 20 years of expertise and achievements in ophthalmology. Prior to Neurotech, Dr. Schiffman was Vice President of Global Drug Development and Therapeutic Area Head of Ophthalmology at Allergan where he was instrumental in the global development and approval of many successful products including Restasis®, Combigan®, Lumigan®, Acuvail®/Acular®, Zymaxid®/Zymar®, as well as Lumigan® and Ganfort® unit dose products.
Envisia Therapeutics Announces Management Changes
Mar 10 15
Envisia Therapeutics announced that it has named Benjamin Yerxa, PhD as the company’s president, effective immediately. Dr. Yerxa joined Liquidia Technologies in August 2012 and was critical to the company’s formation of Envisia in November 2013 where he has since served in the dual role of chief scientific officer for both companies. Neal Fowler will remain chief executive officer of Liquidia Technologies and serve as a director on the Envisia Board of Directors. Throughout his 25-year career in the pharmaceutical and biotechnology industry, Dr. Yerxa has been involved with the discovery and development of several investigational new drugs (INDs), phase 3 clinical programs, new drug applications (NDAs) and drug approvals. His experience spans a variety of therapeutic areas including ophthalmology, pulmonary, cardiovascular and HIV. Dr. Yerxa has more than 50 U.S. patents to his name, led a variety of licensing deals and has built several R&D and corporate functions from inception. The company also announced the appointment of Gary Phillips, M.D. as executive chairman of the company’s board of directors. Dr. Phillips has been a director of the board since July 2014 and brings more than 20 years of experience in strategy, business development and licensing, commercial operations, business analytics, and clinical medicine in the pharmaceutical and healthcare industries. He is currently the senior vice president and chief strategy officer at Mallinckrodt Pharmaceuticals.
Envisia Therapeutics Inc. Initiates Phase 2a Clinical Trial for ENV515 in Patients with Glaucoma
Jan 27 15
Envisia Therapeutics Inc. announced that it has initiated a phase 2a clinical trial to investigate the safety and tolerability of its lead product, ENV515, in patients with
glaucoma. ENV515 is a proprietary, fully biodegradable PRINT® (Particle Replication In Non-Wetting Templates) particle formulation of a prostaglandin analog, travoprost, with the potential for sustained intraocular pressure (IOP) reduction over as many as six months. ENV515 offers the potential to significantly address the poor compliance that exists among glaucoma patients to limit disease progression and vision loss. The progress made with ENV515 underscores the power and flexibility of the PRINT technology to rapidly develop and advance promising product candidates, simultaneously, across multiple areas of interest in ophthalmology. The phase 2a clinical trial is designed as an open-label study that will enroll 20 glaucoma patients at sites within the US. Results from this clinical trial are anticipated by mid-2015.
Similar Private Companies By Industry
Recent Private Companies Transactions
|No transactions available in the past 12 months.|